Skip to main content
    Z

    Zimmer Biomet Holdings Inc (ZBH)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NYSE

    $102.11
    +0.70 (+0.69%)

    Market Cap: $19.53B

    Last updated: Nov 17, 2026 at 4:34 PM ET

    Zimmer Biomet Holdings Inc (ZBH) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Zimmer Biomet Holdings (ZBH) has a market cap of $19.53B and an enterprise value of $26.64B. Its share count is down 3.84% from a year earlier. Its return on invested capital of 5.04% compares with a 11.05% median across 8 similar companies.

    Total Valuation

    Enterprise value is 36.37% above the market cap, as debt exceeds cash.

    Market Cap$19.53B
    Enterprise Value$26.64B
    Latest price (Nov 17, 2026)$102.11

    Key Dates

    The next earnings report is expected on Feb 8, 2027, covering the quarter ending Dec 31, 2026. The last ex-dividend date was Sep 30, 2026.

    Next Earnings DateFeb 8, 2027 (expected)
    Last Earnings DateNov 4, 2026
    Last Ex-Dividend DateSep 30, 2026
    Last Payment DateOct 30, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count fell 0.88% in the quarter ended Sep 30, 2026 and shrank 2.96% a year over 2 years.

    Shares Outstanding190.50M
    Shares Change (YoY)-3.84%
    Shares Change (QoQ)-0.88%
    Share Count Growth (2Y CAGR)-2.96%

    Valuation Ratios

    Sales and book value multiples are 2.3x and 1.5x. Its year-end P/E ranged from 11.0x to 27.2x from 2016 to 2025.

    P/E Ratio12.0x
    Forward P/E11.8x
    P/S Ratio2.3x
    Forward P/S2.3x
    P/B Ratio1.5x
    P/FCF Ratio11.8x
    P/OCF Ratio10.4x
    PEG Ratio2.1

    Valuation history and multiples

    Enterprise Valuation

    Counting debt and cash, the company is valued at 11.6x EBITDA and 16.2x free cash flow.

    EV / Earnings34.7x
    EV / Sales3.1x
    EV / EBITDA11.6x
    EV / EBIT22.7x
    EV / FCF16.2x

    Price Statistics

    The stock is up 14.47% over 52 weeks and trades 6.45% above its 50-day average.

    Beta (1Y)0.43
    52-Week Change+14.47%
    1-Month Change+7.50%
    3-Month Change+1.63%
    6-Month Change+19.26%
    5-Year Change-33.96%
    10-Year Change-10.32%
    Total Return (1Y)+15.55%
    Total Return (3Y CAGR)-2.11%
    Total Return (5Y CAGR)-3.19%
    Return vs SPY (1Y)+3.98%
    Max Drawdown (1Y)-21.20%
    Max Drawdown (3Y)-38.99%
    Sharpe Ratio (1Y)0.45
    Correlation with SPY (1Y)0.18
    50-Day Average$95.92
    200-Day Average$92.39
    52-Week Range$78.70 to $112.55
    RSI (14 Days)53.6
    Average Volume (20 Days)2.62M

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 1.46x current liabilities, and total debt is 0.59x shareholder equity.

    Current Ratio1.46x
    Quick Ratio0.79x
    Debt / Equity0.59x
    Debt / EBITDA3.29x
    Debt / FCF4.57x
    Interest Coverage4.07x

    Returns and Efficiency

    Return on invested capital is 5.04% over the last 12 months, against a 5-year average of 4.70%.

    Return on Equity (ROE)6.04%
    Return on Assets (ROA)3.26%
    Return on Invested Capital (ROIC)5.04%
    Return on Capital Employed (ROCE)5.86%
    ROE (5Y Average)5.22%
    ROA (5Y Average)2.97%
    ROIC (5Y Average)4.70%
    Asset Turnover0.36x
    Inventory Turnover1.12x
    Receivables Turnover4.78x
    Cash Conversion Cycle352 days

    Taxes

    Income tax took 13.08% of pretax income over the last 12 months.

    Income Tax (TTM)$115.70M
    Effective Tax Rate13.08%

    Scores

    ZBH has an Altman Z-Score of 2.41, in the grey zone from 1.81 to 2.99, and a Piotroski F-Score of 5 of 9, in the average band of 3 to 7.

    Altman Z-Score2.41
    Altman Z ZoneGrey
    Piotroski F-Score5 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue of $8.57B over the last 12 months is up 6.98% from the 12 months before.

    Revenue$8.57B
    Revenue Growth (YoY)+6.98%
    Gross Profit$5.97B
    Operating Income$1.16B
    Pretax Income$884.50M
    Net Income$767.40M
    EBITDA$2.28B
    EBIT$1.17B
    Reported EPS (TTM)$8.48

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 54.04% of the $23.54B in total assets.

    Cash and Equivalents$399.90M
    Total Debt$7.50B
    Net Debt$7.10B
    Net Debt Per Share$37.29
    Working Capital$1.63B
    Shareholder Equity$12.72B
    Book Value Per Share$66.75
    Tangible Book Value-$2.25B
    Total Assets$23.54B
    Total Liabilities$10.81B

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $241.10M of capital spending, operating cash flow left $1.64B of free cash flow.

    Operating Cash Flow$1.88B
    Capital Expenditures$241.10M
    Free Cash Flow$1.64B
    FCF Per Share$8.62
    Depreciation and Amortization$1.11B
    Dividends Paid$186.70M
    Share Repurchases$829.30M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is 13.55%, against a 5-year average of 14.00%.

    Gross Margin69.68%
    Operating Margin13.55%
    Pretax Margin10.32%
    Net Margin8.95%
    EBITDA Margin26.60%
    EBIT Margin13.69%
    FCF Margin19.18%
    Gross Margin (5Y Average)71.03%
    Operating Margin (5Y Average)14.00%
    Net Margin (5Y Average)8.68%

    Growth

    Revenue grew 5.85% a year over 3 years, and EPS 5.97% a year.

    Revenue Growth (3Y CAGR)+5.85%
    Revenue Growth (5Y CAGR)+6.08%
    EPS Growth (3Y CAGR)+5.97%
    EPS Growth (5Y CAGR)+7.66%
    FCF Growth (3Y CAGR)+8.02%
    FCF Growth (5Y CAGR)+8.85%
    Operating Income Growth (3Y CAGR)+16.40%
    Book Value Per Share Growth (2Y CAGR)+3.51%

    Revenue and profit by year

    Dividends and Yields

    ZBH pays out 9.70% of earnings as dividends.

    Dividend Per Share (Annual)$0.96
    Dividend Yield0.94%
    Payment ScheduleQuarterly
    Dividend Growth (3Y CAGR)0.00%
    Dividend Growth (5Y CAGR)0.00%
    Payout Ratio9.70%
    FCF Payout Ratio11.36%
    Earnings Yield8.33%
    FCF Yield8.45%
    Buyback Yield4.12%
    Shareholder Yield5.08%

    Full dividend history

    Peer Position

    Against 9 similar companies, ZBH has the 9th highest P/E.

    P/E Ratio12.0x vs 22.0x median
    P/S Ratio2.3x vs 3.0x median
    ROIC5.04% vs 11.05% median
    Revenue Growth (Trailing 4 Quarters, YoY)+6.98% vs +8.50% median
    Dividend Yield0.94% vs 0.00% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 3.97% and EPS growth at 4.61% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+3.97%
    EPS Growth Forecast (2Y CAGR)+4.61%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewUndervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About ZBH

    What is ZBH's market cap?

    Zimmer Biomet Holdings has a market cap of $19.53B. Its enterprise value, which adds debt and subtracts cash, is $26.64B.

    What is ZBH's P/E ratio?

    Zimmer Biomet Holdings has a trailing P/E ratio of 12.0x and a forward P/E of 11.8x.

    How many shares of ZBH are outstanding?

    Zimmer Biomet Holdings has 190.50M shares outstanding. The count is down 3.84% from a year earlier.

    Does ZBH pay a dividend?

    Yes. Zimmer Biomet Holdings pays $0.96 a share a year, a dividend yield of 0.94%.

    How much debt does ZBH have?

    Zimmer Biomet Holdings has $7.50B of total debt and $399.90M of cash and equivalents, a net debt position of $7.10B.